Effect of sarcopenia and frailty on outcomes among patients with brain metastases

Purpose Sarcopenia and frailty have been associated with increased mortality and duration of hospitalization in cancer. However, data investigating these effects in patients with brain metastases remain limited. This study aimed to investigate the effects of sarcopenia and frailty on clinical outcom...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of neuro-oncology 2024-03, Vol.167 (1), p.169-180
Hauptverfasser: Lim, Mervyn Jun Rui, Zhang, Zheting, Zheng, Yilong, Khoo, Ivan Wei Loon, Ying, Rhianne Caitlin Vaz Xin, Koh, Sophie Jia Qian, Lim, Ethanyn, Ngam, Pei Ing, Soon, Betsy, Low, Ying Liang, Tan, Li Feng, Teo, Kejia, Nga, Vincent Diong Weng, Yeo, Tseng Tsai
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Purpose Sarcopenia and frailty have been associated with increased mortality and duration of hospitalization in cancer. However, data investigating these effects in patients with brain metastases remain limited. This study aimed to investigate the effects of sarcopenia and frailty on clinical outcomes in patients with surgically treated brain metastases. Methods Patients who underwent surgical resection of brain metastases from 2011 to 2019 were included. Psoas cross-sectional area and temporalis thickness were measured by two independent radiologists (Cronbach’s alpha > 0.98). Frailty was assessed using the Clinical Frailty Scale (CFS) pre-operatively and post-operatively. Overall mortality, recurrence, and duration of hospitalization were collected. Cox regression was performed for mortality and recurrence, and multiple linear regression for duration of hospitalization. Results 145 patients were included, with median age 60.0 years and 52.4% female. Psoas cross-sectional area was an independent risk factor for overall mortality (HR = 2.68, 95% CI 1.64–4.38, p 
ISSN:0167-594X
1573-7373
DOI:10.1007/s11060-023-04542-w